ArticleStem cells translational medicine2025
Effects of MSC-derived extracellular vesicles and dupilumab on the spleen and skin in a house dust mite-induced atopic dermatitis model.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Cannabidiol-DominantNutrients · 2026Article
- Chaga Mushroom (Journal of microbiology and biotechnology · 2026Article
- Thermosensitive Hydrogel Enables Noninvasive Extracellular Vesicle Therapy for Atopic Dermatitis.Biomaterials research · 2026Article
- Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized as a biphasic T-lymphocyte-mediated disease involving T-helper cells. Dupilumab is a human monoclonal antibody that inhibits Th2-related cytokines and has recently been approved for patients with AD. However, the effects of dupilumab are relatively narrow in scope, primarily targeting cytokine-driven inflammatory pathways, with few reported systemic effects. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) could serve as an alternative therapeutic strategy for AD. This study aims to compare the effects of a single subcutaneous injection of EVs and biweekly subcutaneous injection of dupilumab on the skin and spleen in a house dust mite-induced model of AD. Clinical and histological analyses, including H&E and toluidine blue staining, showed that both EVs and dupilumab ameliorated AD in an animal model. Biodistribution analysis through live animal imaging revealed that subcutaneously injected EVs can migrate to the spleen, and flow cytometry analysis showed that EVs restored the splenic ratio of CD4+/CD8 + and spleen enlargement. Cytokine analysis of the skin and spleen showed that EVs effectively regulated both Th2 and Th1 responses, while dupilumab had limited effects on Th1 response. Further, mechanistic analyses revealed that both EVs and dupilumab ameliorated AD via the JAK/STAT signaling pathway. Thus, a single subcutaneous injection of EVs was equally effective as a biweekly subcutaneous injection of dupilumab in ameliorating AD. While dupilumab specifically targets and inhibits the Th2 immune response, clinical-scale EV therapeutics can regulate a broad spectrum of immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.